HPV

Silent cancers: here’s what you need to know when there are no obvious symptoms

Retrieved on: 
星期三, 四月 3, 2024

Contrary to common perception, cancer does not always announce its presence through overt symptoms or obvious signs.

Key Points: 
  • Contrary to common perception, cancer does not always announce its presence through overt symptoms or obvious signs.
  • While even silent cancers can sometimes be aggressive and advance rapidly, they can also remain dormant for years or even decades.
  • Some prostate, breast and thyroid cancers, for example, often evolve slowly without obvious symptoms or spreading beyond the original area.

The importance of early diagnosis

  • Whatever the cancer, it’s always important to get an early diagnosis though – and for silent cancers, this is obviously a challenge.
  • But such symptoms can be misinterpreted or easily dismissed, which contributes to delayed diagnosis and treatment.
  • Fortunately, in many countries including the UK, we have screening tests for diseases like breast or colon cancer, to increase early diagnoses.
  • Early diagnosis is a key factor for successful cancer treatment.

Biomarker discovery

  • From molecular profiling to liquid biopsy techniques (blood tests to diagnose cancer), innovative approaches are reshaping the landscape of cancer diagnosis, offering new avenues for personalised and precision medicine.
  • For example, I worked with a team using blood tests to identify cancers in more than 1,000 women recalled after screening for mammography.
  • Although there’s increasing awareness and use of this approach in Europe, it isn’t standard in the UK.


Justin Stebbing does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Microbix Unveils Test Controls for Head and Neck Cancer

Retrieved on: 
星期一, 三月 11, 2024

While HPV is best known for causing cancers of the cervix in women, this virus family also causes cancer in other bodily tissues.

Key Points: 
  • While HPV is best known for causing cancers of the cervix in women, this virus family also causes cancer in other bodily tissues.
  • Such further types of HPV-driven cancer include those of the “Head and Neck,” collectively tumours inside and behind the nose, throughout the mouth (including the tongue, gums, and palate), all sections of the throat, and the voice box.
  • Unfortunately, a lack of standardized and reproducible reference samples makes it challenging to control the recommended test workflows for diagnosing such cancers.
  • These standardized and reproducible tissue-oriented test controls will then be added to Microbix’s catalogue of QAPs, expanding its activities into support of oncology workflows alongside its wide range of infectious disease test controls.

Jhpiego pledges support to countries working to eliminate cervical cancer

Retrieved on: 
星期三, 三月 6, 2024

Baltimore, Md., March 06, 2024 (GLOBE NEWSWIRE) -- On the eve of International Women’s Day, Jhpiego joined a historic wave of commitments to ending cervical cancer as a public health problem as part of the global Cervical Cancer Elimination Initiative meeting in Cartagena de Indias, Colombia .

Key Points: 
  • Baltimore, Md., March 06, 2024 (GLOBE NEWSWIRE) -- On the eve of International Women’s Day, Jhpiego joined a historic wave of commitments to ending cervical cancer as a public health problem as part of the global Cervical Cancer Elimination Initiative meeting in Cartagena de Indias, Colombia .
  • Jhpiego is also committed in supporting at least five other countries for HPV vaccine coverage improvement and/or implementation of tailored interventions to increase HPV vaccine coverage.
  • Jhpiego has long been committed to integrated programs that link improved screening and treatment for cervical cancer as well as accelerating vaccine uptake.
  • We are inspired by these new commitments to work together across the whole spectrum of cervical cancer responses; together we have the potential to save many more women’s lives.”

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Retrieved on: 
星期二, 二月 27, 2024

REHOVOT, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) --   Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced clinical results from its Phase 1/2 dose escalation study of NT219 in combination with cetuximab in the treatment of patients with recurrent/metastatic head and neck cancer (R/M SCCHN).

Key Points: 
  • The Phase 1/2 dose escalation study (NCT04474470) evaluated NT219 as a monotherapy in various indications and in combination with cetuximab in the treatment of R/M SCCHN and colorectal cancer.
  • As of cut-off date of January 25, 2024:
    Seventeen patients with R/M SCCHN were enrolled in the combination arm of NT219 + cetuximab.
  • The median number of prior lines of therapy was 2 and 94% of the patients received prior immunotherapy.
  • “We were encouraged to see anti-tumor activity in HPV negative patients,” said Dr. Michael Schickler, Purple Biotech’s Head of Clinical and Regulatory Affairs.

Prevent Cancer Foundation awards $1 million in new research grants

Retrieved on: 
星期三, 二月 21, 2024

Alexandria, Va., Feb. 21, 2024 (GLOBE NEWSWIRE) -- The Prevent Cancer Foundation® is pleased to announce new funding for ten scientists who are researching cancer prevention and early detection.

Key Points: 
  • Alexandria, Va., Feb. 21, 2024 (GLOBE NEWSWIRE) -- The Prevent Cancer Foundation® is pleased to announce new funding for ten scientists who are researching cancer prevention and early detection.
  • Read on for more on the 2024 research grantees or access more detailed information on their projects in the researcher database.
  • Having a family history of cancer can affect the age at which cancer screening begins and genetic testing recommendations.
  • To view all past funded research grant and fellowship projects driving these key advancements in cancer prevention and early detection, explore the Prevent Cancer Foundation’s Award Database.

Nielsen Biosciences Announces Enrollment of First Patient in Phase 3 Trial of CANDIN for the Treatment of Common Warts

Retrieved on: 
星期二, 三月 5, 2024

Nielsen BioSciences, Inc. (“Nielsen”), a privately-held, San Diego-based biopharmaceutical company, today announced the first patient enrolled in CFW-3A – a Phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of CANDIN® for the treatment of Verruca vulgaris (common warts) in adolescents and adults.

Key Points: 
  • Nielsen BioSciences, Inc. (“Nielsen”), a privately-held, San Diego-based biopharmaceutical company, today announced the first patient enrolled in CFW-3A – a Phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of CANDIN® for the treatment of Verruca vulgaris (common warts) in adolescents and adults.
  • Nielsen is partnering with Maruho Co. Ltd. (“Maruho”) in the clinical development program for CANDIN.
  • “The first patient treated with CANDIN represents a major milestone for the company, and for patients affected by common warts around the world,” said David P. Burney, PhD, MBA, President and Chief Operating Officer at Nielsen BioSciences.
  • Common warts are estimated to affect approximately 10 percent of the global population.1 There are currently no FDA-approved prescription treatments.

Fujirebio Europe Expands Its Portfolio With Introduction of the Innovative PreCursor-M AnoGYN assay (RUO) for Methylation Testing in Anal Specimens

Retrieved on: 
星期二, 三月 5, 2024

Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.

Key Points: 
  • Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.
  • In analogy with cervical cancer screening, the screening and treatment of HSIL to prevent anal cancer in high-risk groups are under debate.
  • Host cell deoxyribonucleic acid methylation markers for the detection of high-grade anal intraepithelial neoplasia and anal cancer.
  • Analytical validation and diagnostic performance of the ASCL1/ZNF582 methylation test for detection of high-grade anal intraepithelial neoplasia and anal cancer.

Naveris Announces New Data at ASTRO Multidisciplinary Head and Neck Cancers Symposium 2024

Retrieved on: 
星期三, 二月 28, 2024

Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, today announced new data to be presented at The American Society for Radiation Oncology (ASTRO) Multidisciplinary Head and Neck Cancers Symposium (MHNCS) in Phoenix, AZ from February 29 – March 2, 2024.

Key Points: 
  • Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, today announced new data to be presented at The American Society for Radiation Oncology (ASTRO) Multidisciplinary Head and Neck Cancers Symposium (MHNCS) in Phoenix, AZ from February 29 – March 2, 2024.
  • The test provides a non-invasive and precise method for identifying HPV-driven cancers before there is clinical or radiographical evidence of disease.
  • Data supporting the clinical validity and utility of NavDx have been published in nearly 20 peer-reviewed publications.
  • "The data being showcased highlight the critical role circulating tumor HPV DNA assessment can play in shaping patient care strategies.

UT Health San Antonio secures $16.4 million from CPRIT over six months, adding transformative expertise, bolstering cancer research

Retrieved on: 
星期五, 三月 8, 2024

SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) (https://uthscsa.edu/) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas (https://www.cprit.state.tx.us/about-us) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.

Key Points: 
  • SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) ( https://uthscsa.edu/ ) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas ( https://www.cprit.state.tx.us/about-us ) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.
  • The Mays Cancer Center at UT Health San Antonio ( https://cancer.uthscsa.edu/ ) is one of only four National Cancer Institute-designated Cancer Centers in Texas.
  • The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas.
  • The Greehey Children's Cancer Research Institute ( https://cancer.uthscsa.edu/gccri ) is one of only two institutes in the United States dedicated solely to pediatric cancer research.

Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR Test

Retrieved on: 
星期四, 三月 7, 2024

SALT LAKE CITY, March 7, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its SARAPLEX™ Influenza Multiplex (IFM) Test Kit to clinical laboratories as an in vitro diagnostic ("IVD") for the detection and differentiation of Influenza A and Influenza B.

Key Points: 
  • Co-Primers utilize a unique design architecture to combat common issues with real-time PCR that can lead to inaccurate results, specifically primer dimer propagation, and which are magnified in multiplex reactions.
  • "The importance of accurate, reliable PCR testing at the high-throughput clinical laboratory level remains critical," remarked Dwight Egan, CEO of Co-Diagnostics.
  • *The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.
  • The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA.